Related societies have published guidance on diagnosis and treatment of AstraZeneca's new coronavirus vaccine, which is considered to be at risk of blood clots in extremely rare cases.
The AstraZeneca vaccine, which was approved last month, was pointed out that there is a very rare risk of blood clots after vaccination, and the Ministry of Health, Labor and Welfare has decided not to use it for public vaccination for the time being, and the treatment method and recommended age. We are carefully considering such things.
Under these circumstances, the Japan Stroke Society and the Japan Thrombosis and Hemostasis Society, at the request of the Ministry of Health, Labor and Welfare, created a guide for diagnosis and treatment for medical institutions and released it on the 2nd of this month.
The guide states that there is no established diagnosis or treatment method at this time, and that treatment will be started promptly if a decrease in the number of platelets or a blood clot is confirmed as a result of blood tests and diagnostic imaging. ..
For treatment, it is recommended to administer a drug called an "immunoglobulin preparation" according to the test results, and after consulting with a specialist, it is requested to consider the administration of a drug that suppresses blood clots.
On the other hand, administration of a drug called "heparin" and blood transfusion are avoided.
The Ministry of Health, Labor and Welfare plans to consider using it for public inoculation in the future with reference to this guide.
The Japan Stroke Society says, "It is necessary to distinguish it from other diseases, and it is difficult to make a reliable diagnosis and treatment, but I would like you to refer to it when inoculation begins."
Government plans to supply to each country and region Some voices request domestic utilization
The vaccine of AstraZeneca, the government and that no standing time of the prospect to be used in the country, from the fact that all of the national content of the vaccine became a prospect that can be secured by the end of the year, such as through international framework to distribute the vaccine , to prospect 3000 million doses, shows the idea to be supplied to each country or region.
On the other hand, academic societies have called for its use in Japan, and the Japan Vaccine Society, which is made up of researchers involved in vaccine development and clinical trials, announced its views at the end of last month.
According to this, while vaccination is an urgent issue all over the world, it is pointed out that it is not internationally understood not to use vaccines that are already used in each country and approved in Japan. ..
In addition, the inoculation target is selected based on age, gender, presence of underlying disease, etc., citing the advantages such as the fact that production has started in Japan and that it is easier to store in a refrigerator than other approved vaccines. We are asking you to make the most of it.